Safety and efficacy results from a first-in-human, phase 1/2 study of ASKG915, an anti-PD-1/pro-IL-15 bifunctional fusion protein, for patients with advanced solid tumors.

ASKG915 - Aosaikang Pharma

https://www.asco.org/abstracts-presentations/257814

Jiajia Li; Jianfeng Lu; Xiaohua Wu; Jian Zhang; Lin Wu; Xianli Yin; Anwen Xiong; Xiubao Ren; Jianzhen Shan; Luwei Han; Jing Chen

Apr 21, 2026